linjc16/ctgov huggingface dataset:
Advanced Analysis of the Carotid Phonoangiography and Diseases

Study Overview
=================
Brief Summary
-----------------
Purpose: To investigate the different sound spectrum of carotid arteries and to analyze its relationship to the vessel disease, and to build a new biomarker about vascular disorder. Methods: To record the carotid phonoangiography with digital stereoscopy and analysis the spectrum with different algorithm such as FFT, wavelet, entropy, complexity, and HHT. The results will be correlated and comparison to the finding in clinical, carotid Doppler and duplex, CTA, MR, and catheter angiography. Statistics: The significance of difference between parameters was computed using t-tests or paired t-test etc. A p value <0.05 is defined as significant.

Detailed Description
-----------------
The investigators plan to recruit data from patients that come to their department for angiography study and intervention (n=300) with different disease entity such as atherosclerosis, tumor, aneurysm, arteriovenous malformation or fistula, and other vascular disorders. A period of about 20 seconds of the carotid phonoangiography was recorded. Standard for comparison: catheter angiography, CTA, MRI/MRA. The degree of stenosis, the wall thickness, SI and density change was clustered and compared. The clinical and laboratory data will be reviewed and the vascular risk factors will be calculated. Spectrum analysis: The sound spectrum will be analysis with the FFT, wavelet, entropy, complexity, and HHT algorithms. The correlation between change of spectrums and also the correlated clinical, images, and laboratory change will be further analysis by statistic method.

Official Title
-----------------
Advanced Analysis of the Carotid Phonoangiography and Diseases

Conditions
-----------------
Carotid Atherosclerosis, Seeing Sounds as Colors, Stenosis, Stroke

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age: 20 years old to 99 years old Gender: Unlimited Because different types of brain diseases, those who received conventional catheter vascular examination. Exclusion Criteria: Neck inflammation locally who can not admit the sound. Due to inability to cooperate to accept those recordings.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| progression of stenosis | Follow-up the severity of the carotid stenosis and correlate its wall change | three years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| wall change | correlate the phonographic change with the follow up CTA wall change. | three years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sound, carotid artery, stenosis, wall, stroke
Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis

Study Overview
=================
Brief Summary
-----------------
To investigate the efficacy and safety of PARIET twice daily (b.i.d.) in patients with Proton Pump Inhibitor-resistant reflux esophagitis

Official Title
-----------------
Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis

Conditions
-----------------
Refractory Reflux Esophagitis

Intervention / Treatment
-----------------
* Drug: rabeprazole sodium


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria; -Proton pump inhibitor-resistant reflux esophagitis. (Patients who have mucosal breaks (erosions, ulcers) on endoscopy) Exclusion criteria; Patients with a history of hypersensitivity to any ingredients of PARIET. Patients on atazanavir sulfate.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Rabeprazole Sodium<br> | Drug: rabeprazole sodium<br>* Doses of 10 mg or 20 mg twice daily may be administered orally to reflux esophagitis patients for a further 8 weeks when proton pump inhibitor treatment is ineffective. However, a dose of 20 mg twice daily should only be administered to patients with severe mucosa injury.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of subjects with improvement based on health related Quality of Life (QOL) questionnaire |  | Check at predose, 4, 8, 16 and 32 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of subjects with improvement in symptoms of GERD |  | Check at predose, 4, 8, 16 and 32 weeks | 
| Endoscopic healing rate |  | 8 weeks | 
| Adverse events |  | Every 4-8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
rabeprazole sodium, refractory reflux esophagitis
Efficacy Study of Minoxidil Lotion Versus Combined Minoxidil and Finasteride Lotion to Treat Male Pattern Hair Loss

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the efficacy of 3% Minoxidil lotion and 3% Minoxidil with 0.1% Finasteride lotion for 6 months in male pattern hair loss.

Official Title
-----------------
Efficacy of 3% Minoxidil Versus Combined 3% Minoxidil and 0.1% Finasteride for Male Pattern Hair Loss: a Randomized, Double-blinded, Comparative Study

Conditions
-----------------
Androgenetic Alopecia

Intervention / Treatment
-----------------
* Drug: 3%Minoxidil lotion
* Drug: 3% Minoxidil with 0.1% Finasteride lotion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male, age 18-15 years androgenetic alopecia grade 3V to 5 ( Norwood-Hamilton classification) Exclusion Criteria: use minoxidil in 6 months use finasteride in 12 months use ketoconazole, tar, selenium shampoo, topical tretinoin, topical steroid in 2 weeks seborrheic dermatitis or psoriasis on scalp history of allergy to minoxidil, finasteride

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Minoxidil<br> | Drug: 3%Minoxidil lotion<br>* 3% Minoxidil lotion apply two times a day<br>|
| Active Comparator: MinoxidilFinasteride<br> | Drug: 3% Minoxidil with 0.1% Finasteride lotion<br>* 3% Minoxidil with 0.1% Finasteride lotion apply two times a day.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The mean change of hair count from baseline and 6 months | Total hair count on the vertex is measured on 1 cm2 circular area. The mean change in hair count is compared at baseline and 6 months.The significance of change is determined by Unpaired t Test. | baseline and 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Global photographic assessment by dermatologists | Photographs of the vertex scalp are taken at baseline and 6 months. A panel of 3 dermatologists assesssed the change in hair growth using a 7-point scale. | baseline and 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
minoxidil, finasteride, topical, lotion, male pattern hair loss, androgenetic alopecia
The Study Of CT Scans and Echo Parameters in Patients With PAH

Study Overview
=================
Brief Summary
-----------------
Current standard of the diagnosis and monitoring of PHNT requiring combination of invasive and non-invasive tests. The goal of the study is to correlate data from CT scans, echocardiograms, right heart catheterization, PFTs, sleep studies, and perfusion scans. The ultimate goal is to determine patterns of the PAH disease processes.

Detailed Description
-----------------
The goal of our study is to correlate data from various non-invasive tests such as commuted tomography (CT) imaging, echocardiogram, Pulmonary Function Tests, and other laboratory tests along with hemodynamic measurements from Right Heart Catheterizations in these ILD patients with Pulmonary Hypertension, as well as all other pulmonary hypertension. The ultimate goal is to determine patterns of the PAH disease processes, as well as define optimal diagnostic modalities including in-hospital verses outpatient studies.

Official Title
-----------------
The Study of CT Scan and Echocardiogram Parameters in Patients With Pulmonary Hypertension With Regards to Hemodynamics, Sleep Studies, and Various Laboratory Markers.

Conditions
-----------------
Pulmonary Hypertension

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pulmonary Hypertension; ILD with Pulmonary Hypertension Exclusion Criteria: NON-PH

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| I,A<br>I=Pulmonary Hypertension Patients A=ILD patients with Pulmonary Hypertension Patients | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Study Of CT Scans and Echo Parameters in Patients With PAH | Correlation of Pulmonary artery diameter as measured by CT scan and Pulmonary artery systolic pressure as measured by Echocardiogram. | All data has been previously collected. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pulmonary Hypertension;, ILD;, CT Imaging;, Echocardiogram;, Hemodynamic measurements of RHC., Pulmonary Function Tests
Radiotherapy of Pelvic Lymph Nodes in High Risk Prostate Cancer - A Retrospective Analysis

Study Overview
=================
Brief Summary
-----------------
Men with high risk prostate cancer who underwent radiotherapy of the prostate/seminal vesicles or underwent postoperative radiotherapy including pelvic lymph nodes between 2010 and 2016 are analyzed retrospectively. The aims are to estimate progression-free survival as well as toxicity according to CTCAE v4.03.

Detailed Description
-----------------
Collection of data and retrospective analysis of patients with high risk prostate cancer treated with radiotherapy to pelvic lymph nodes. What influence has irradiation of pelvic lymph nodes on patients with high risk prostate cancer in terms of progression free survival and toxicity. How does this influence side effects with respect to gastrointestinal (proctitis, abdominal pain, diarrhea) and genitourinary (cystitis, urinary disorders) toxicities (CTCAE v4.03)

Official Title
-----------------
Retrospektive Analyse Der Radiotherapie Des Pelvinen Lymphabflusses Beim Lokalisierten Prostatakarzinom Vom Hochrisikotyp Anhand Der Klinikdatenbank 2010-2016

Conditions
-----------------
Prostatic Neoplasms Benign, Radiotherapy Side Effect, Lymph Node Disease

Intervention / Treatment
-----------------
* Radiation: Radiotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men with high risk prostate cancer treated with radiotherapy to prostate/seminal vesicles or postoperative radiotherapy and pelvic lymph nodes at the Kantonssptial Graubuenden, Department of Radiation Oncology between 2010 and 2016 Exclusion Criteria: Men with prostate cancer other than high risk disease and no radiotherapy to pelvic lymph nodes

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Radiotherapy<br>Radiation to prostate/seminal vesicles including pelvic lymph nodes Postoperative radiation to prostate bed including pelvic lymph nodes | Radiation: Radiotherapy<br>* Radiation to prostate/seminal vesicles including pelvic lymph nodes Postoperative radiation to prostate bed including pelvic lymph nodes<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival | PSA progession-free survival will be measured | through study completion, an average of 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Toxicity (CTCAE v4.03) | GI, GU Toxicities as well as Erectile Dysfunction will be measured | through study completion, an average of 2 years |
A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days.

Study Overview
=================
Brief Summary
-----------------
To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152) and to establish the MTD at each of the different dosing schedules.

Detailed Description
-----------------
Patients receive intravenous DS-4152 by infusion twice weekly for 21 days, followed by 2 weeks of rest; courses may repeat. Patients undergo weekly follow-up. A punch biopsy will be obtained from patients with Kaposi's sarcoma.

Official Title
-----------------
A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days.

Conditions
-----------------
Sarcoma, Kaposi, HIV Infections

Intervention / Treatment
-----------------
* Drug: Tecogalan sodium


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Patients must have: Kaposi's sarcoma plus HIV infection OR metastatic solid tumor. Life expectancy of at least 12 weeks. NO symptomatic AIDS-defining opportunistic infection within the past 4 weeks. Recovered from toxicity of any prior anticancer therapy. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Leukemia or lymphoma. Current gastrointestinal bleeding by stool guaiac. Extensive bone metastases or significant radiographic osteoporosis in patients with solid tumors. Active heart disease such as uncontrolled angina, uncompensated congestive heart failure, or dysrhythmias requiring antiarrhythmics. Acute intercurrent infection other than genital herpes. Symptomatic or known central nervous system involvement (including brain metastases) unless stable and off therapy. Concurrent Medication: Excluded: Other anticancer therapy. Other investigational agents. Patients with the following prior conditions are excluded: History of acute or chronic gastrointestinal bleeding or inflammatory bowel disease. History of myocardial infarction within past 6 months. Prior Medication: Excluded: Anticancer therapy within the past 3 weeks (6 weeks for nitrosourea or mitomycin C). Investigational agents within the past 4 weeks.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Tecogalan sodium|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Neoplasms, Sarcoma, Kaposi, Acquired Immunodeficiency Syndrome, Antineoplastic Agents, tecogalan
Cardiovascular Mortality Associated With Abnormal Calcium Metabolism

Study Overview
=================
Brief Summary
-----------------
The purpose of this cohort study is to estimate the risk of cardiovascular mortality associated with abnormal calcium metabolism

Official Title
-----------------
Cardiovascular Mortality Associated With Abnormal Calcium Metabolism

Conditions
-----------------
Cardiovascular Disease, Kidney Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
All ESRD patients who indicated dialysis in 1990-1993

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Calcium Metabolism
Evaluation of the Dexcom G6 Continuous Glucose Monitoring System With a Non-Interferent Sensor

Study Overview
=================
Brief Summary
-----------------
The objective of the study is to demonstrate effectiveness of the G6 sensor membrane, in preventing acetaminophen's interference effect on glucose sensing.

Detailed Description
-----------------
The interference effect of the sensor will be evaluated by comparing the bias in the glucose values exhibited from the G6 CGM system after administration of acetaminophen. Bias will be evaluated by comparing CGM values to a laboratory referenceusing venous sample measurements.

Official Title
-----------------
Evaluation of the Dexcom G6 Continuous Glucose Monitoring System With a Non-Interferent Sensor

Conditions
-----------------
Diabetes Mellitus

Intervention / Treatment
-----------------
* Device: Acetaminophen Challenge (G6 CGM)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ages 18 or older Diagnosis of diabetes Exclusion Criteria: Pregnancy Known gastroparesis Abnormal liver function

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: CGM Users<br>Prospective, non-randomized, single-arm. Continuous Glucose Monitoring. Acetaminophen challenge is the intervention. | Device: Acetaminophen Challenge (G6 CGM)<br>* Evaluation of acetaminophen effect on CGM glucose sensing<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Interference Effect for the G6 CGM | Bias of sensor to reference measurement pre and post acetaminophen administration | 6 hrs post dose | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean of sensor minus YSI values (bias) for various time periods | Bias calculated for pre-dose, post dose and peak post dose | 6 hrs post dose | 
| Duration of interference effect for the G6 CGM | Length of time the inhibition effect is more than 10 mg/dL | 6 hrs post dose |
Quality of Life After Enhanced Recovery Protocol for Colorectal Surgery

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to investigate the quality of life and satisfaction of patient who underwent colorectal surgery using an enhanced recovery protocol when back home. In this retrospective study patients will be telephoned and asked to answer a questionnaire.

Detailed Description
-----------------
Since October 1st 2015, our center has been labelled reference center for colorectal surgery using Enhanced Recovery Protocol (ERP) by GRACE (Groupe francophone de Rehabilitation après ChirurgiE; a francophone counterpart of ERAS® society). In case of ERP, the quality of life when the patient is at home is not well known. Some argue that patient might experience discomfort and lack of autonomy, particularly elderly patient if discharged home too quickly. In this study, the investigators will call our patients introduced in the database of GRACE to assess the quality of life and patient satisfaction concerning our ERP. Eight domains will be investigated: information, stress, feelings when discharged home, pain, fatigue, autonomy, feeding problems, and satisfaction. When analyzing the results the investigators will pay a particular attention to elderly patients (age > 70 yo) to determine whether these experience more difficulties as compared to younger patients.

Official Title
-----------------
Quality of Life and Satisfaction of Patients Discharged Home After Enhanced Recovery Protocol for Colorectal Surgery

Conditions
-----------------
Surgery

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patients included in our GRACE database Exclusion Criteria: No exclusion criteria
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life (0 to ten numeric scale + questionnaire) | 0 to ten numeric scale + questionnaire | first month after leaving the hospital | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Satisfaction (0 to ten numeric scale + questionnaire) | 0 to ten numeric scale + questionnaire | first month after leaving the hospital | 
| Pain (0 to ten numeric scale + questionnaire) | 0 to ten numeric scale + questionnaire | first month after leaving the hospital | 
| Fatigue (0 to ten numeric scale + questionnaire) | 0 to ten numeric scale + questionnaire | first month after leaving the hospital | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
colorectal surgery, enhanced recovery